title: The interface between cholinergic pathways and the immune system and its relevance to arthritis.
abstract: The nervous and immune systems are likely to be interacting in arthritis, with the possible involvement of both neural and non-neural cholinergic transmission. Centrally acting muscarinic agonists, electrical stimulation of the vagus and treatment with nicotinic receptor agonists can all act systemically to reduce inflammation, although the responsible pathways are incompletely understood. While this 'cholinergic anti-inflammatory pathway' is widely viewed as a significant pathophysiological mechanism controlling inflammation, the evidence supporting this view is critically reviewed and considered inconclusive; an alternative pathway via sympathetic nerves is implicated. This review also discusses how cholinergic pathways, both neural and non-neural, may impact on inflammation and specifically arthritis. Nicotinic agonists have been reported to reduce the incidence and severity of murine arthritis, albeit an observation we could not confirm, and clinical studies in rheumatoid arthritis have been proposed and/or are underway. While the therapeutic potential of nicotinic agonists and vagal stimulation is clear, we suggest that the 'cholinergic anti-inflammatory pathway' should not be uncritically embraced as a significant factor in the pathogenesis of rheumatoid arthritis.
authors.affiliation: Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, 3010, Australia. rmca@florey.edu.au.
authors.forename: Robin M
authors.initials: RM
authors.lastname: McAllen
authors.affiliation: Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, 3010, Australia. adcook@unimelb.edu.au.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Cook
authors.affiliation: Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, 3010, Australia. h.khiew@student.unimelb.edu.au.
authors.forename: Hsu Wei
authors.initials: HW
authors.lastname: Khiew
authors.affiliation: Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, 3010, Australia. dmartelli@gmail.com.
authors.forename: Davide
authors.initials: D
authors.lastname: Martelli
authors.affiliation: Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, 3010, Australia. jahami@unimelb.edu.au.
authors.forename: John A
authors.initials: JA
authors.lastname: Hamilton
mesh_terms: D000818:Animals; D001172:Arthritis, Rheumatoid / Q000276:immunology* / Q000503:physiopathology*; D017776:Autonomic Pathways / Q000502:physiology; D018678:Cholinergic Agents / Q000276:immunology; D002799:Cholinergic Fibers / Q000276:immunology / Q000502:physiology; D059329:Cholinergic Neurons / Q000276:immunology* / Q000502:physiology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007107:Immune System / Q000378:metabolism / Q000503:physiopathology; D007249:Inflammation / Q000276:immunology* / Q000503:physiopathology; D008297:Male; D051379:Mice; D011950:Receptors, Cholinergic / Q000187:drug effects; D012680:Sensitivity and Specificity
chemical_list: D018678:Cholinergic Agents; D011950:Receptors, Cholinergic